Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547033 | 1.00 | POLB (0.48) | POLBLMNAHPGDKMT2APDK2 | |
| SCHEMBL3547423 | 0.93 | LMNA (0.47) | POLBLMNAHPGDKMT2APDK2 | |
| SCHEMBL3547425 | 0.93 | LMNA (0.47) | POLBLMNAHPGDKMT2APDK2 | |
| SCHEMBL201319 | 0.85 | POLB (0.49) | POLBLMNAHPGDKMT2AHCRTR1 | |
| SCHEMBL3551395 | 0.85 | POLB (0.49) | POLBLMNAHPGDKMT2AHCRTR1 | |
| SCHEMBL3544419 | 0.84 | PDK2 (0.45) | POLBLMNAHPGDKMT2APDK2 | |
| Hydroxyamine SCHEMBL5238906 | 0.84 | LMNA (0.50) | POLBLMNAHPGDKMT2A | |
| Hydroxyamine SCHEMBL5238910 | 0.84 | LMNA (0.50) | POLBLMNAHPGDKMT2A | |
| SCHEMBL3545845 | 0.83 | HCRTR1 (0.46) | POLBPDK2HCRTR1HCRTR2GAA | |
| SCHEMBL3545842 | 0.83 | HCRTR1 (0.46) | POLBPDK2HCRTR1HCRTR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | POLB 516/4885LMNA 3400/4885HPGD 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.